AVE — Avecho Biotechnology Share Price
0.000.00%
Last trade - 00:00- AU$19.02m
- AU$17.72m
- AU$1.13m
- 51
- 14
- 54
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.82 | ||
| Price to Tang. Book | 5.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.01% | ||
| Return on Equity | -64.72% | ||
| Operating Margin | -275.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.38 | 0.79 | 1.13 | 0.47 | 1.13 | n/a | n/a | -23.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Directors
- Gregory Collier NEC
- Paul Gavin CEO
- Roksan Libinaki COO
- Melanie Leydin SEC
- Ross Murdoch NED (54)
- Matthew McNamara NED
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 19th, 1992
- Public Since
- August 9th, 1993
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 3,169,297,013
- Address
- Unit A8, 2A Westall Road, Clayton, MELBOURNE, 3168
- Web
- https://avecho.com.au/
- Phone
- +61 390025000
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for AVE
Half Year 2025 Avecho Biotechnology Ltd Earnings Release
Similar to AVE
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Avecho Biotechnology share price?
As of Today at 18:26 UTC, shares in Avecho Biotechnology are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Avecho Biotechnology share price performed this year?
Shares in Avecho Biotechnology last closed at AU$0.01 and the price had moved by +50% over the past 365 days. In terms of relative price strength the Avecho Biotechnology share price has outperformed the ASX All Ordinaries Index by +47.22% over the past year.
What are the analyst and broker recommendations for Avecho Biotechnology?
There is no consensus recommendation for this security.
Find out moreWhat is the Avecho Biotechnology dividend yield?
Avecho Biotechnology does not currently pay a dividend.
Does Avecho Biotechnology pay a dividend?
Avecho Biotechnology does not currently pay a dividend.
When does Avecho Biotechnology next pay dividends?
Avecho Biotechnology does not currently pay a dividend.
How do I buy Avecho Biotechnology shares?
To buy shares in Avecho Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avecho Biotechnology?
As of the previous close price of AU$0.01, shares in Avecho Biotechnology had a market capitalisation of AU$19.02m.
Where are Avecho Biotechnology shares listed?
Here are the trading details for Avecho Biotechnology:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AVE
What kind of share is Avecho Biotechnology?
Based on an overall assessment of its quality, value and momentum Avecho Biotechnology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avecho Biotechnology share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Avecho Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avecho Biotechnology. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +140.39%.
As of the last closing price of AU$0.01, shares in Avecho Biotechnology were trading +87.5% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avecho Biotechnology PE Ratio?
The Avecho Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avecho Biotechnology?
Avecho Biotechnology's management team is headed by:
- Gregory Collier - NEC
- Paul Gavin - CEO
- Roksan Libinaki - COO
- Melanie Leydin - SEC
- Ross Murdoch - NED
- Matthew McNamara - NED